2016
DOI: 10.1007/s13738-015-0804-8
|View full text |Cite
|
Sign up to set email alerts
|

Palladium complexes: new candidates for anti-cancer drugs

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

1
31
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 71 publications
(35 citation statements)
references
References 137 publications
1
31
0
Order By: Relevance
“…This composition was selected due to the high antimicrobial effect of silver and for the anticancer properties of platinum. 16,17 The antibacterial activity of silver nanoparticles is based on the penetration of the cell membrane, which suppress the respiratory enzyme. 18 Additionally, nanoparticles interfere with the DNA inside the bacteria cells, preventing the replication and transcription of the genetic material.…”
Section: Introductionmentioning
confidence: 99%
“…This composition was selected due to the high antimicrobial effect of silver and for the anticancer properties of platinum. 16,17 The antibacterial activity of silver nanoparticles is based on the penetration of the cell membrane, which suppress the respiratory enzyme. 18 Additionally, nanoparticles interfere with the DNA inside the bacteria cells, preventing the replication and transcription of the genetic material.…”
Section: Introductionmentioning
confidence: 99%
“…The anticancer activity of cisplatin (cis‐diamminedichloroplatinum(II)) was discovered by Barnett Rosenberg and coworkers in 1969, which has been used extensively for different types of neoplasms including head, neck, ovarian, bladder, endometrial, cervical, testicular, osteogenic sarcoma, and lung cancers . After using cisplatin as an antitumor agent successfully, many other complexes containing platinum or other metals such as, vanadium, ruthenium, copper, iron, cobalt, palladium, rhodium, zinc, and nickel have been proposed with selectivity and cytotoxicity toward tumor cells…”
Section: Introductionmentioning
confidence: 99%
“…[20] The anticancer activity of cisplatin (cis-diamminedichloroplatinum(II)) was discovered by Barnett Rosenberg and coworkers in 1969, [21] which has been used extensively for different types of neoplasms including head, neck, ovarian, bladder, endometrial, cervical, testicular, osteogenic sarcoma, and lung cancers. [22] After using cisplatin as an antitumor agent successfully, many other complexes containing platinum or other metals such as, vanadium, [23] ruthenium [23] , copper, [23] iron, [24] cobalt, [25] palladium, [26] rhodium, [27] zinc, [27] and nickel have been proposed with selectivity and cytotoxicity toward tumor cells. [27] Gold(III) complexes with chelating N-donor ligands are the first gold(III) complexes examined for anticancer applications, [28] in vitro pharmacological studies point out that some of these novel gold(III) complexes are highly cytotoxic toward cultured human tumor cell lines, [29] pyridine-based complexes were tested in vitro against a panel of cancer cell lines and HeLa cancer cells.…”
Section: Introductionmentioning
confidence: 99%
“…[13][14][15] However, it has side effects such as nephrotoxicity, drug tolerance, limited solubility and intravenous administration. [14,[16][17][18][19] Due to the fact that the cancer is the second leading cause of death, [16,20,21] the development of improved metal based drugs is currently of interest.…”
Section: Introductionmentioning
confidence: 99%